Belcher Tells Fed. Circ. Inequitable Conduct Order Implausible
Law360 (August 14, 2020, 4:57 PM EDT) -- A district court erroneously found that Belcher Pharmaceuticals LLC obtained an epinephrine injection patent through inequitable conduct, disregarding a more plausible explanation for why it didn't disclose prior art during prosecution, the drug company has told the Federal Circuit.
In its opening appeal brief filed Thursday, Belcher contends the reason why inventor Darren Rubin did not disclose three prior art references to the U.S. Patent and Trademark Office during the patent's prosecution was not because it intended to deceive the USPTO, as the district court found, but because they were not material to the claimed invention.
"The court's rejection of this...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!